Compare AIRS & PROF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIRS | PROF |
|---|---|---|
| Founded | 2012 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 328.7M | 263.8M |
| IPO Year | 2021 | 2017 |
| Metric | AIRS | PROF |
|---|---|---|
| Price | $2.76 | $7.35 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | ★ 385.4K | 115.0K |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.89 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $151,818,000.00 | $16,098,000.00 |
| Revenue This Year | $5.19 | $92.40 |
| Revenue Next Year | $5.32 | $64.10 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 50.73 |
| 52 Week Low | $1.51 | $3.92 |
| 52 Week High | $12.00 | $8.95 |
| Indicator | AIRS | PROF |
|---|---|---|
| Relative Strength Index (RSI) | 26.09 | 50.16 |
| Support Level | $2.40 | $6.17 |
| Resistance Level | $3.36 | $7.93 |
| Average True Range (ATR) | 0.32 | 0.52 |
| MACD | -0.10 | 0.01 |
| Stochastic Oscillator | 9.44 | 38.40 |
AirSculpt Technologies Inc is a next-generation body contouring treatment designed to optimize both comfort and precision, available exclusively at AirSculpt offices. The minimally invasive procedure removes fat and tightens skin while sculpting targeted areas of the body, allowing for quick healing with minimal bruising, tighter skin, and precise results. Its proprietary and patented AirSculpt method is minimally invasive because it requires no needle, no scalpel, no stitches, and no general anesthesia. It offers fat removal procedures across treatment areas and fat transfer procedures that use the patient's own fat cells to enhance the breasts, buttocks, hips or other areas and do not require silicone or foreign materials to be implanted. Its segment is direct medical procedure services.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.